Pain prevalence and characteristics in survivors of solid cancers: a systematic review and meta-analysis

Haenen, Vincent; Evenepoel, Margaux; Baerdemaecker, Tom De; Meeus, Mira; Devoogdt, Nele; Morlion, Bart; Dams, Lore; Dijck, Sophie Van; Gucht, Elien Van der; Vrieze, Tessa De; Vyvere, Thijs Vande; Groef, An De

doi:10.1007/s00520-022-07491-8

Cited by 22 publications

(13 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). In the treatment period with a double-dummy procedure, the patients took bilayer tablets (active drug or placebo) twice daily (morning and evening) and IR capsules (placebo or active drug) four times per day (morning, noon, evening, and before bed) according to the random allocation method in a blinded manner for up to 14 days (study days [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. The rationale for the 14-day treatment period is described in the Supplementary Methods.…”

Section: Methodsmentioning

confidence: 99%

“…Pain is a common symptom in cancer patients; some studies suggested that almost half of patients experience pain at least 3 months after completing curative treatment, and nearly a third experience moderate to severe pain [ 1 , 2 ]. Cancer pain may be caused by the cancer itself or metastases, or may be related to the treatments (e.g., surgical pain, neuropathic pain after chemotherapy) [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

Shinkai,

Katsumata,

Kawai

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

Purpose We investigated whether twice-daily administration of a bilayer tablet formulation of tramadol (35% immediate-release [IR] and 65% sustained-release) is as effective as four-times-daily IR tramadol capsules for managing cancer pain. Methods This randomized, double-blind, double-dummy, active-comparator, non-inferiority study enrolled opioid-naïve patients using non-steroidal anti-inflammatory drugs or acetaminophen (paracetamol) to manage cancer pain and self-reported pain (mean value over 3 days ≥ 25 mm on a 100-mm visual analog scale [VAS]). Patients were randomized to either bilayer tablets or IR capsules for 14 days. The starting dose was 100 mg/day and could be escalated to 300 mg/day. The primary endpoint was the change in VAS (averaged over 3 days) for pain at rest from baseline to end of treatment/discontinuation. Results Overall, 251 patients were randomized. The baseline mean VAS at rest was 47.67 mm (range: 25.6–82.7 mm). In the full analysis set, the adjusted mean change in VAS was − 22.07 and − 19.08 mm in the bilayer tablet (n = 124) and IR capsule (n = 120) groups, respectively. The adjusted mean difference was − 2.99 mm (95% confidence interval [CI] − 7.96 to 1.99 mm). The upper 95% CI was less than the predefined non-inferiority margin of 7.5 mm. Other efficacy outcomes were similar in both groups. Adverse events were reported for 97/126 (77.0%) and 101/125 (80.8%) patients in the bilayer tablet and IR capsule groups, respectively. Conclusion Twice-daily administration of bilayer tramadol tablets was as effective as four-times-daily administration of IR capsules regarding the improvement in pain VAS, with comparable safety outcomes. Clinical trial registration JapicCTI-184143/jRCT2080224082 (October 5, 2018).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

Shinkai,

Katsumata,

Kawai

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Pain is a frequent and distressing symptom among cancer patients [ 1 , 2 ]. Pain in these patients may be due to their disease, its treatment, or nonmalignant causes.…”

Section: Introductionmentioning

confidence: 99%

Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital

Rozman de Moraes,

Erdogan,

Azhar

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: Our aim was to examine the frequency and prescription pattern of breakthrough (BTO) and scheduled (SCH) opioids and their ratio (BTO/SCH ratio) of use, prior to and after referral to an inpatient supportive care consult (SCC) for cancer pain management (CPM). Methods and Materials: Patients admitted at the MD Anderson Cancer Center and referred to a SCC were retrospectively reviewed. Cancer patients receiving SCH and BTO opioids for ≥24 h were eligible for inclusion. Patient demographics and clinical characteristics, including the type and route of SCH and BTO opioids, daily opioid doses (MEDDs) of SCH and BTO, and BTO/SCH ratios were reviewed in patients seen prior to a SCC (pre-SCC) and during a SCC. A normal BTO ratio was defined as 0.5–0.2. Results: A total of 665/728 (91%) patients were evaluable. Median pain scores (p < 0.001), BTO MEDDs (p < 0.001), scheduled opioid MEDDs (p < 0.0001), and total MEDDs (p < 0.0001) were higher, but the median number of BTO doses was fewer (2 vs. 4, p < 0.001), among patients seen at SCC compared to pre-SCC. A BTO/SCH ratio over the recommended ratio (>0.2) was seen in 37.5% of patients. The BTO/SCH ratios in the pre-SCC and SCC groups were 0.10 (0.04, 0.21) and 0.17 (0.10, 0.30), respectively, p < 0.001. Hydromorphone and Morphine were the most common BTO and SCH opioids prescribed, respectively. Patients in the early supportive care group had higher pain scores and MEDDs. Conclusions: BTO/SCH ratios are frequently prescribed higher than the recommended dose. Daily pain scores, BTO MEDDs, scheduled opioid MEDDs, and total MEDDs were higher among the SCC group than the pre-SCC group, but the number of BTO doses/day was lower.

show abstract

“…Over 70–80% of patients affected by tumors is reported to suffer from cancer pain in meta-analyses concerned with cancer pain prevalence in a 40 year-period [ 5 , 6 ]; this pain is unbearable in up to 33% of patients [ 7 ] and reaches the 95% rate in patients affected by advanced disease (see [ 8 ]), making cancer pain a major problem in the management of oncologic patients. Moreover, the latest systematic review dealing with pain prevalence in cancer survivors dates back to 2022 [ 9 ]: it underlines that pain prevalence in solid tumor survivors that had finished treatment at least 3 months earlier is 47%, with a heterogeneity of 98.99% among studies. These data support the importance of cancer pain treatment for the management and the improvement of quality of life of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis

Corasaniti

Bagetta

Morrone

et al. 2023

IJMS

View full text Add to dashboard Cite

Over 80% of patients affected by cancer develops cancer-related pain, one of the most feared consequences because of its intractable nature, particularly in the terminal stage of the disease. Recent evidence-based recommendations on integrative medicine for the management of cancer pain underline the role of natural products. The present systematic review and meta-analysis aims at appraising for the first time the efficacy of aromatherapy in cancer pain in clinical studies with different design according to the most updated Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 recommendations. The search retrieves 1002 total records. Twelve studies are included and six are eligible for meta-analysis. The present study demonstrates significant efficacy of the use of essential oils in the reduction of the intensity of pain associated with cancer (p < 0.00001), highlighting the need for earlier, more homogeneous, and appropriately designed clinical trials. Good certainty body of evidence is needed for effective and safe management of cancer-related pain using essential oils by establishment of a step-by-step preclinical-to-clinical pathway to provide a rational basis for clinical use in integrative oncology. PROSPERO registration: CRD42023393182.

show abstract

Pain prevalence and characteristics in survivors of solid cancers: a systematic review and meta-analysis

Cited by 22 publications

References 70 publications

Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital

Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About